Chimeric Therapeutics Limited (ASX: CHM) Request for trading halt In accordance with ASX Listing Rule 17.1, Chimeric Therapeutics Limited (ASX: CHM) (the Company) requests that its securities be placed into an immediate trading halt pending an announcement in relation to new data for the ADVENT-AML Phase 1B clinical trial (NCT05834244). The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Monday, 19 May 2025, whichever is the earlier. The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt. Please contact me if you require any further information. Yours sincerely Phillip Hains Joint Company Secretary
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)